Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials
Even at lower doses, GLP-1s carry risks of gastrointestinal issues, including nausea, constipation, and general abdominal discomfort
GLP-1 products, originally developed to treat type 2 diabetes, but are now FDA-approved specifically for obesity under brand names like Wegovy and Zepbound, are "significantly contributing to overall plan costs", CVS spokesperson Phillip Blando told FOX Business
Semaglutide: We talked about the SUSTAIN-6 trial which showed semaglutides potential for an average of 5% weight loss on the smallest dose, kicking the hysteria off
Lifestyle interventions Morning sunlight, stress regulation, minimising toxin exposure, better sleep, and gentle movement can all together help calm an overactive immune response
When compared to some other diabetes treatments, studies have shown that it can take 8 weeks to reach an A1C target of 7% and 12 weeks to reach an A1C 6.5% with Mounjaro